Response to 'EMANCIPATE study: Drawing conclusions may be difficult in the absence of fundamental information' and 'EMANCIPATE versus EXPO different results can be explained by differing study designs' [3]

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 2, 2008, Pages 153-155

  Goh, Khean Lee ^a   Benamouzig, Robert ^b   Sander, Peter ^b   Schwan, Thomas ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Department of Gastroenterology   (France)

^c Nycomed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE; PLACEBO;

CLINICAL STUDY; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; ENDOSCOPY; EPIGASTRIC PAIN; ESOPHAGUS PH; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LETTER; MAINTENANCE THERAPY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; STOMACH PH; VOMITING;

EID: 38049146063     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f3a19f     Document Type: Letter

References (22)

1. Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut 2004; 53 (Suppl IV):iv58-iv65.
2. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion. Gut 2004; 53 (Suppl IV):iv24.
3. French National Society of Gastroenterology, GERD in adults: diagnostic and treatment [in French]. Gastroentérologie Clinique et Biologique 1999; 23:1-8.
4. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, et al. Esomeprazole 20 mg versus pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22:803-811.
5. Bruley des Varannes S, Galmiche J-P. Symptoms and quality of life in GERD: why and how to measure [in French]. Hepato-Gastro 2007; 14:7-9.
6. Bardhan KD, Berghöfer P. Look - but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment. Digestion 2007; 75 (Suppl 1):87-100.
7. Fass R, Bothe G, Heinze H, Mönnikes H. Pantoprazole improves symptoms of gastroesophageal reflux disease beyond heartburn. Gut 2007; 56(Suppl III):A215.
8. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32:97-99.
9. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32:965-973.
10. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319:550-553.
11. Galmiche JP, Shi G, Simon B, Casset-Semanza F, Slama A. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther 1998; 12:909-917.
12. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al.; on the behalf of the Genval Workshop Group. AN evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999; 44 (Suppl 2):S1-S16.
13. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003; 98 (3 Suppl):S31-S39.
14. Armstrong D, Mönnikes H, Bardhan KD, Stanghellini V. The construction of a new evaluative GERD questionnaire: methods and state-of-the-art. Digestion 2004; 70:71-78.
15. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H. Evaluation of GERD symptoms during therapy. Part 1. Development of the new GED questionnaire ReQuest. Digestion 2004; 69:229-237.
16. Mönnikes H, Bardhan KD, Stanghellini V, Berghöfer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy. Part 2. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69:238-244.
17. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20:891-898.
18. Stanghellini V, Armstrong D, Mönnikes H, Berghöfer P, Gatz G, Bardhan KD. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion 2005; 71:145-151.
19. Stanghellini V, Armstrong D, Monnikes H, Bardhan K, Schmitt H, Velten I, et al. Objective definition of symptom relief in clinical studies: determination of international GERD symptom thresholds based on ReQuest. Gastroenterology 2006; 130 (Suppl 2):A455.
20. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21:739-746.
21. Gillessen A. Balanced perspective essential in erosive esophagitis treatment. Aliment Pharmacol Ther 2005; 22:889-890.
22. Labenz J. Balanced perspective essential in erosive esophagitis treatment; author reply. Aliment Pharmacol Ther 2005; 22:890-891.